1. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. (May 2020) Authors: Berger, Martin D.; Ning, Yan; Stintzing, Sebastian; Heinemann, Volker; Cao, Shu; Zhang, Wu; Yang, Dongyun; Miyamoto, Yuji; Suenaga, Mitsukuni; Schirripa, Marta; Hanna, Diana L.; Soni, Shivani; Puccini, Alberto; Tokunaga, Ryuma; Naseem, Madiha; Battaglin, Francesca; Cremolini, Chiara; Falcone, Alf... Journal: European journal of cancer Issue: Volume 131(2020) Page Start: 89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A still missing piece of the FIRE-3 puzzle – Authors' reply. Issue 12 (December 2016) Authors: Stintzing, Sebastian; Heinemann, Volker Journal: Lancet oncology Issue: Volume 17:Issue 12(2016:Dec.) Page Start: e516 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. (November 2016) Authors: Heinemann, Volker; Rivera, Fernando; O'Neil, Bert H.; Stintzing, Sebastian; Koukakis, Reija; Terwey, Jan-Henrik; Douillard, Jean-Yves Journal: European journal of cancer Issue: Volume 67(2016) Page Start: 11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta‐analysis using TRIBE, MAVERICC and FIRE3. Issue 8 (26th March 2019) Authors: Tokunaga, Ryuma; Cao, Shu; Naseem, Madiha; Battaglin, Francesca; Lo, Jae Ho; Arai, Hiroyuki; Loupakis, Fotios; Stintzing, Sebastian; Puccini, Alberto; Berger, Martin D; Soni, Shivani; Zhang, Wu; Mancao, Christoph; Salhia, Bodour; Mumenthaler, Shannon M; Weisenberger, Daniel J.; Liang, Gangning; C... Journal: International journal of cancer Issue: Volume 145:Issue 8(2019) Page Start: 2082 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Author's reply to: "Prognostic value of cetuximab related skintoxicity in metastatic colorectal cancer patients and its correlation with parameters of the EGFR signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group". Issue 7 (18th September 2012) Authors: Stintzing, Sebastian; Heinemann, Volker Journal: International journal of cancer Issue: Volume 132:Issue 7(2013:Apr. 01) Page Start: 1719 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. (May 2017) Authors: Berger, Martin D.; Yamauchi, Shinichi; Cao, Shu; Hanna, Diana L.; Sunakawa, Yu; Schirripa, Marta; Matsusaka, Satoshi; Yang, Dongyun; Groshen, Susan; Zhang, Wu; Ning, Yan; Okazaki, Satoshi; Miyamoto, Yuji; Suenaga, Mitsukuni; Lonardi, Sara; Cremolini, Chiara; Falcone, Alfredo; Heinemann, Volker; L... Journal: European journal of cancer Issue: Volume 77(2017) Page Start: 13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. (June 2021) Authors: Bourhis, Jean; Stein, Alexander; Paul de Boer, Jan; Van Den Eynde, Marc; Gold, Kathryn A.; Stintzing, Sebastian; Becker, Jürgen C.; Moran, Michael; Schroeder, Andreas; Pennock, Gregory; Salmio, Satu; Esser, Regina; Ciardiello, Fortunato Journal: Cancer treatment reviews Issue: Volume 97(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?. (1st February 2022) Authors: Mayr, Christian; Kiesslich, Tobias; Modest, Dominik Paul; Stintzing, Sebastian; Ocker, Matthias; Neureiter, Daniel Journal: Expert opinion on investigational drugs Issue: Volume 31:Number 2(2022) Page Start: 221 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer. (6th October 2021) Authors: Trojan, Jörg; Stintzing, Sebastian; Haase, Oliver; Koch, Christine; Ziegler, Paul; Demes, Melanie; Jelas, Ivan Journal: Oncologist Issue: Volume 26:Number 12(2021) Page Start: e2110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Complete Pathological Response After Neoadjuvant Short‐Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI‐H/dMMR Rectal Cancer. (6th October 2021) Authors: Trojan, Jörg; Stintzing, Sebastian; Haase, Oliver; Koch, Christine; Ziegler, Paul; Demes, Melanie; Jelas, Ivan Journal: Oncologist Issue: Volume 26:Number 12(2021) Page Start: e2110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗